Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Fibrosis is a condition with globally high unmet medical need, and as such is a highly active area of academic and pharmaceutical research covering multiple treatment targets, organs, tissues and therapeutic approaches. Anti-fibrotic Drug Discovery is a single source reference for the latest drug-discovery approaches to tackle fibrosis in various tissues, comprehensively covering recent success and future perspectives on emerging therapeutic intervention points. The book highlights significant pre-clinical and clinical drugs currently being developed globally for this disorder. This book is…mehr
Fibrosis is a condition with globally high unmet medical need, and as such is a highly active area of academic and pharmaceutical research covering multiple treatment targets, organs, tissues and therapeutic approaches. Anti-fibrotic Drug Discovery is a single source reference for the latest drug-discovery approaches to tackle fibrosis in various tissues, comprehensively covering recent success and future perspectives on emerging therapeutic intervention points. The book highlights significant pre-clinical and clinical drugs currently being developed globally for this disorder. This book is ideal for postgraduate students and researchers with an interest in anti-fibrotic drug discovery as well as clinicians specialising in liver, kidney, heart and lung disease, in which fibrosis plays a key role in pathology.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, D ausgeliefert werden.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Inhaltsangabe
TGFß Signaling Targeting the av Integrins in Fibroproliferative Disease Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor Activators Autotaxin Inhibitors in Fibrosis Inhibition of LOXL2 and Other Lysyl Oxidase (Like) Enzymes: Intervention at the Core of Fibrotic Pathology Targeting the Ubiquitin Proteasome System in Pulmonary Fibrosis Galectin-3 Involvement in Fibrotic Diseases Emerging Role of CXCR4 in Fibrosis BH3 Mimetic Drugs for Anti-fibrotic Therapy Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities Targeting Fibroblasts in Fibrosis and Cancer
TGFß Signaling Targeting the av Integrins in Fibroproliferative Disease Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor Activators Autotaxin Inhibitors in Fibrosis Inhibition of LOXL2 and Other Lysyl Oxidase (Like) Enzymes: Intervention at the Core of Fibrotic Pathology Targeting the Ubiquitin Proteasome System in Pulmonary Fibrosis Galectin-3 Involvement in Fibrotic Diseases Emerging Role of CXCR4 in Fibrosis BH3 Mimetic Drugs for Anti-fibrotic Therapy Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities Targeting Fibroblasts in Fibrosis and Cancer
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826